Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial-Reference-Cited by-同舟云学术

Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial

Published:2013-09 Issue:10 Volume:14 Page:1020-1026
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Katsumata Noriyuki,Yasuda Makoto,Isonishi Seiji,Takahashi Fumiaki,Michimae Hirofumi,Kimura Eizo,Aoki Daisuke,Jobo Toshiko,Kodama Shoji,Terauchi Fumitoshi,Sugiyama Toru,Ochiai Kazunori

Publisher

Elsevier BV

Subject

Oncology

Reference18 articles.

1. First-line therapy in ovarian cancer trials;Thigpen;Int J Gynecol Cancer,2011

2. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial;Katsumata;Lancet,2009

3. Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas;Yedema;Tumour Biol,1992

4. Letter: creatinine clearance: bedside estimate;Jelliffe;Ann Intern Med,1973

5. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide;Rustin;J Clin Oncol,2006

Cited by 400 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epidemiology of Gynaecological Cancer: Ovarian, Endometrial and Cervical;International Encyclopedia of Public Health;2025

2. British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-09

3. A single institutional clinical outcome for stages III and IV ovarian cancer patients treated with dose‐dense TC therapy in the frontline or first platinum‐sensitive relapse setting;Journal of Obstetrics and Gynaecology Research;2024-07-02

4. Artificial Intelligence-Based Histopathological Subtyping of High-Grade Serous Ovarian Cancer;The American Journal of Pathology;2024-07

5. The prognostic and predictive value of homologous recombination deficiency status in patients with advanced stage epithelial ovarian carcinoma after first-line platinum-based chemotherapy;Frontiers in Oncology;2024-06-10